The profitability of Albany Molecular's (AMRI +9.9%) "core business could reach historic...


The profitability of Albany Molecular's (AMRI +9.9%) "core business could reach historic levels," Sterne Agee says, citing the expected "resurgence in preclinical-PI activity over the next several years." Analyst Greg Bolan resumes coverage at Buy with a $15 price target.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs